MX9700560A - Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. - Google Patents

Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.

Info

Publication number
MX9700560A
MX9700560A MX9700560A MX9700560A MX9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A MX 9700560 A MX9700560 A MX 9700560A
Authority
MX
Mexico
Prior art keywords
retroviral
transdominant negative
hiv
treatment
integrase gene
Prior art date
Application number
MX9700560A
Other languages
English (en)
Inventor
Tod Paul Holler
Annette Meyer
Gary Jan Nabel
Leonard Post
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9700560A publication Critical patent/MX9700560A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método de uso de genes integrasa negativos transdominantes para hacer al menos una célula resistente a infecciones retrovirales que incluyen infecciones retrovirales que resultan del VIH; un método de introducir un gene integrasa negativo transdominante en al menos una célula mamífera a dicha célula resistente a una infeccion retroviral así como vectores, células y métodos para construir las mismas utiles en los métodos antes citados; un método para tratar al SIDA que comprende la administracion a un paciente de una cantidad efectiva de un gen integrasa negativo transdominante solo o combinado con agentes utiles para la terapia de genes para la inhibicion de VIH, agentes antivirales o interlequina-2; y métodos de suministro farmacéutico que incluyen un gene integrasa negativo transdominante solo o combinado con agentes utiles para la terapia de genes de inhibicion de VIH, agentes antivirales o interleuquina-2.
MX9700560A 1994-08-05 1995-07-19 Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. MX9700560A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28657894A 1994-08-05 1994-08-05
PCT/US1995/009110 WO1996004386A1 (en) 1994-08-05 1995-07-19 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection

Publications (1)

Publication Number Publication Date
MX9700560A true MX9700560A (es) 1997-05-31

Family

ID=23099243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700560A MX9700560A (es) 1994-08-05 1995-07-19 Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.

Country Status (6)

Country Link
US (2) US5908923A (es)
EP (1) EP0774003A1 (es)
JP (1) JPH10503654A (es)
CA (1) CA2194488A1 (es)
MX (1) MX9700560A (es)
WO (1) WO1996004386A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004386A1 (en) * 1994-08-05 1996-02-15 Warner-Lambert Company Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU754425B2 (en) * 1997-09-15 2002-11-14 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
IT1297016B1 (it) * 1997-12-23 1999-08-03 San Raffaele Centro Fond Processo di selezione di linfociti t cd4+ per la transduzione di geni anti-hiv
EP1103614B1 (en) * 1999-06-04 2010-06-02 Nippon Institute for Biological Science Novel plasmid vector
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001810A (en) * 1989-11-20 1999-12-14 Eli Lilly And Company Methods for treating retroviral infection
ATE189263T1 (de) * 1990-07-16 2000-02-15 New York Health Res Inst Auswahl von effizient ziel-rns spaltenden ribozymen
AU8657691A (en) * 1990-08-24 1992-03-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The In vitro retroviral integration assay
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1996004386A1 (en) * 1994-08-05 1996-02-15 Warner-Lambert Company Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
US5993972A (en) * 1996-08-26 1999-11-30 Tyndale Plains-Hunter, Ltd. Hydrophilic and hydrophobic polyether polyurethanes and uses therefor

Also Published As

Publication number Publication date
WO1996004386A1 (en) 1996-02-15
CA2194488A1 (en) 1996-02-15
JPH10503654A (ja) 1998-04-07
US6303334B1 (en) 2001-10-16
US5908923A (en) 1999-06-01
EP0774003A1 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
EP1024197A3 (en) Mesothelial cell gene therapy
WO1991003248A3 (en) Method for immune system activation
ATE174514T1 (de) Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
AU1854695A (en) The use of interferon subtypes in the preparation of medicaments to treat viral infections
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
AU690336B2 (en) Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
ZA937147B (en) Heterocyclic amines useful in the therapy of the asthma and of the inflammation of the respiratory tract
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
MY105855A (en) Therapeutic nucleotides.
NZ324157A (en) Conditionally replicating viral vectors and their use in treating HIV
CA2285463A1 (en) A combination therapy for hiv infections
NZ512850A (en) Treatment of papillomavirus infections
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
CA2385872A1 (en) Gene transfer in human lymphocytes using retroviral scfv cell targeting
GEP20012489B (en) Use of Natural Human α-Interferon
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine
AU660916B2 (en) Beta-hydroxamate D-aspartic acid for treatment of viral infections and tumours
AU2396900A (en) Treatment and prevention of hiv and other viral infections
FR2427822A1 (fr) Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine
NZ334634A (en) Use of a protein extracted from mammalian liver for treating HIV
ATE153533T1 (de) Zubereitungen, die acyclovir-ähnliche verbindungen und 2'-vinylsubstituierte nukleosidanaloge enthalten, zur behandlung viraler infektionen
Scheibel Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees